Author:
Marcuello E,Altés A,Menoyo A,del Rio E,Gómez-Pardo M,Baiget M
Publisher
Springer Science and Business Media LLC
Reference25 articles.
1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokohama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxocity: a pharmacogenetic analysis. Cancer Res 60: 6921–6926
2. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T (1998) UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9: 845–847
3. Bissery MC, Vrignaud P, Lavelle F, Chabot GG (1996) Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice. Ann NY Acad Sci 803: 173–180
4. Cunningham D, Pyrhonen S, James RD, Punt CJ, Hickish TF, Heikkila R, Johannsen TB, Starkhammar H, Topham CA, Awad L, Jacques C, Herait P (1998) Randomised trial of irinotecan plus supportive care vs supportive care alone after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 352: 1413–1418
5. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Ivenson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer. Lancet 355: 1041–1047
Cited by
278 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献